VXLLF (Vaxil Bio) Non Operating Income: $0.00 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VXLLF Vaxil Bio Ltd VXLLF
37 GF Score
Price $0.04
! 2 Warning Signs
View Full Analysis

What is Vaxil Bio Non Operating Income?

Vaxil Bio VXLLF 37 Non Operating Income is $0.00 Mil as of Mar. 2026. GuruFocus rates VXLLF with a GF Score™ of 37/100. The stock has 2 warning signs investors should review.

Non Operating Income is income or expense that comes from miscellaneous sources. Vaxil Bio's Non Operating Income for the three months ended in Mar. 2026 was $0.00 Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil.

Vaxil Bio Non Operating Income Related Terms

Vaxil Bio Non Operating Income Historical Data

* Premium members only.

The historical data trend for Vaxil Bio's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vaxil Bio Non Operating Income Chart

Vaxil Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Non Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.44

Vaxil Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Non Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
VXLLF
37GF Score
Vaxil Bio Ltd VXLLF
Non Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vaxil Bio Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Non Operating Income →
What does a Non Operating Income of $0.00 Mil mean?
Vaxil Bio (VXLLF) has a Non Operating Income of $0.00 Mil as of Mar. 2026. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Vaxil Bio and its competitors.
Is Vaxil Bio's Non Operating Income too high?
Vaxil Bio's current Non Operating Income is $0.00 Mil. Overall, Vaxil Bio has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Vaxil Bio's Non Operating Income compare to VRTX and REGN?
Vaxil Bio's Non Operating Income of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Non Operating Income for a Biotechnology company?
A good Non Operating Income depends on the Biotechnology industry context. However, Non Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Non Operating Income mean?
A high Non Operating Income can signal that a stock is expensive relative to its fundamentals. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Vaxil Bio and its competitors. Vaxil Bio's current Non Operating Income is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vaxil Bio stock overvalued right now?
Vaxil Bio (VXLLF) has a current Non Operating Income of $0.00 Mil. The current Non Operating Income is $0.00 Mil. Vaxil Bio's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Non Operating Income calculated?
Non Operating Income is calculated from a company's financial statements. For Vaxil Bio (VXLLF), the current Non Operating Income is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vaxil Bio Business Description

Other Exchanges VXL:Canada
Address 559 Briar Hill Avenue, Toronto, ON, CAN, M5N 1N1
Vaxil Bio Ltd is a biotechnology company focused on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. In recent years, the Company has been more focused on P-EsbpDOX. The Company develops ImMucin, a MUC1 SP-derived vaccine that has completed a Phase 1/2 clinical trial for the treatment of multiple myeloma. It is also developing SP-based COVID-19 and tuberculosis vaccine/treatment candidates.
37GF Score

Get the complete analysis for VXLLF

Non Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.04
Price